Establishment and validation of a predictive nomogram model for non-small cell lung cancer patients with chronic hepatitis B viral infection

Table 2 Univariate analysis of OS in the primary cohorts

Variable	Univariate analysis
Variable	HR (95% CI)	P
Gender
Male	Reference
Female	1.088 (0.678–1.746)	0.726
Age (years)
≤ 42	Reference
> 42	0.316 (0.171–0.587)	< 0.001
Family history
Yes	Reference
No	0.877 (0.512–1.501)	0.631
Smoking behaviour
Yes	Reference
No	0.965 (0.595–1.564)	0.884
BMI
≥ 25	Reference
18.5 ≤ BMI < 25	1.419 (0.757–2.660)	0.275
< 18.5	1.489 (0.480–4.618)	0.491
TNM stage
I	Reference
II	1.058 (0.318–3.517)	0.927
III	3.256 (1.477–7.181)	0.003
IV	6.575 (2.939–14.711)	< 0.001
Size (cm)^d
≤ 6.3	Reference
> 6.3	2.769 (1.503–5.101)	0.001
Treatment
Surgery	Reference
Radiotherapy/chemotherapy	3.737 (1.891–7.387)	< 0.001
Surgery and radiotherapy/chemotherapy	1.049 (0.517–2.126)	0.895
Other	6.845 (2.630–17.818)	< 0.001
ALT (U/L)
≤ 12.5	Reference
> 12.5	0.630 (0.311–1.278)	0.200
AST (U/L)
≤ 22.0	Reference
> 22.0	1.366 (0.849–2.197)	0.198
SLR
≤ 1.24	Reference
> 1.24	1.673 (1.015–2.759)	0.044
APOAI (g/L)
≤ 1.17	Reference
> 1.17	0.393 (0.244–0.633)	< 0.001
APOB (g/L)
≤ 0.99	Reference
> 0.99	0.533 (0.308–0.922)	0.024
ALP (U/L)
≤ 82.9	Reference
> 82.9	1.800 (1.106–2.929)	0.018
ALB (g/L)
≤ 40.1	Reference
> 40.1	0.693 (0.385–1.246)	0.220
GGT (U/L)
≤ 44.2	Reference
> 44.2	2.371 (1.348–4.169)	0.003
LDH (U/L)
≤ 245.6	Reference
> 245.6	3.423 (1.847–6.345)	< 0.001
TBIL (μmol/L)
≤ 13.6	Reference
> 13.6	0.541 (0.276–1.059)	0.073
DBIL (μmol/L)
≤ 3.3	Reference
> 3.3	1.583 (0.974–2.572)	0.064

BMI body mass index, TNM pathological tumour node metastasis stage, ALT alanine transaminase, AST aspartate aminotransferase, SLR AST-to-ALT ratio, APOAI apolipoprotein AI, APOB apolipoprotein B, ALP alkaline phosphatase, ALB albumin, GGT glutamyl transpeptidase, LDH lactic dehydrogenase, TBIL total bilirubin, DBIL direct bilirubin

ISSN: 1479-5876